Evgenia Gurevich1,2, Yael Borovitz1, Shelli Levi1, Sharon Perlman3,4, Daniel Landau5,6. 1. Department of Nephrology, Schneider Children's Medical Center of Israel (SCMCI), 14 Kaplan St, Petach Tikva, 4920235, Israel. 2. Department of Pediatrics, Barzilai Medical Center, Ashkelon, Ben Gurion University of the Negev, Beer Sheva, Israel. 3. Department of Obstetrics, Schneider Women's Hospital, Petach Tikva, Israel. 4. Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel. 5. Department of Nephrology, Schneider Children's Medical Center of Israel (SCMCI), 14 Kaplan St, Petach Tikva, 4920235, Israel. danny_L@clalit.org.il. 6. Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel. danny_L@clalit.org.il.
Abstract
BACKGROUND: Idiopathic infantile hypercalcemia (IIH) etiologies include pathogenic variants in CYP24A1, leading to increased 1,25(OH)2 D, hypercalciuria and suppressed parathyroid hormone (PTH), and in SLC34A1 and SLC34A3, leading to the same metabolic profile via increased phosphaturia. IIH has not been previously described in CKD due to kidney hypodysplasia (KHD). METHODS: Retrospective study of children with bilateral KHD and simultaneously tested PTH and 1,25(OH)2D, followed in a tertiary care center between 2015 and 2021. RESULTS: Of 295 screened patients, 139 had KHD, of them 16 (11.5%) had IIH (study group), 26 with normal PTH and any 1,25(OH)2D were controls. There were no differences between groups' gender, obstructive uropathy rate and baseline eGFR. Study patients were younger [median (IQR) age: 5.2 (3.2-11.3) vs. 61 (13.9-158.3) months, p < 0.001], had higher 1,25(OH)2D (259.1 ± 91.7 vs. 156.5 ± 46.4 pmol/l, p < 0.001), total calcium (11.1 ± 0.4 vs. 10.7 ± 0.3 mg/dl, p < 0.001), and lower phosphate standard deviation score (P-SDS) [median (IQR): - 1.4 (- 1.9, - 0.4) vs. - 0.3 (- 0.8, - 0.1), p = 0.03]. During 12 months of follow-up, PTH increased among the study group (8.8 ± 2.8 to 22.7 ± 12.4 pg/ml, p < 0.001), calcium decreased (11 ± 0.5 to 10.3 ± 0.6 mg/dl, p = 0.004), 1,25(OH)2D decreased (259.5 ± 91.7 to 188.2 ± 42.6 pmol/l, p = 0.1), P-SDS increased [median (IQR): - 1.4 (- 1.9, - 0.4) vs. - 0.3 (- 0.9, 0.4), p = 0.04], while eGFR increased. Five of 9 study group patients with available urine calcium had hypercalciuria. Five patients had nephrocalcinosis/lithiasis. Genetic analysis for pathogenic variants in CYP24A1, SLC34A1 and SLC34A3 had not been performed. CONCLUSIONS: Transient IIH was observed in infants with KHD, in association with hypophosphatemia, resembling SLC34A1 and SLC34A3 pathogenic variants' metabolic profile. A higher resolution version of the Graphical abstract is available as Supplementary information.
BACKGROUND: Idiopathic infantile hypercalcemia (IIH) etiologies include pathogenic variants in CYP24A1, leading to increased 1,25(OH)2 D, hypercalciuria and suppressed parathyroid hormone (PTH), and in SLC34A1 and SLC34A3, leading to the same metabolic profile via increased phosphaturia. IIH has not been previously described in CKD due to kidney hypodysplasia (KHD). METHODS: Retrospective study of children with bilateral KHD and simultaneously tested PTH and 1,25(OH)2D, followed in a tertiary care center between 2015 and 2021. RESULTS: Of 295 screened patients, 139 had KHD, of them 16 (11.5%) had IIH (study group), 26 with normal PTH and any 1,25(OH)2D were controls. There were no differences between groups' gender, obstructive uropathy rate and baseline eGFR. Study patients were younger [median (IQR) age: 5.2 (3.2-11.3) vs. 61 (13.9-158.3) months, p < 0.001], had higher 1,25(OH)2D (259.1 ± 91.7 vs. 156.5 ± 46.4 pmol/l, p < 0.001), total calcium (11.1 ± 0.4 vs. 10.7 ± 0.3 mg/dl, p < 0.001), and lower phosphate standard deviation score (P-SDS) [median (IQR): - 1.4 (- 1.9, - 0.4) vs. - 0.3 (- 0.8, - 0.1), p = 0.03]. During 12 months of follow-up, PTH increased among the study group (8.8 ± 2.8 to 22.7 ± 12.4 pg/ml, p < 0.001), calcium decreased (11 ± 0.5 to 10.3 ± 0.6 mg/dl, p = 0.004), 1,25(OH)2D decreased (259.5 ± 91.7 to 188.2 ± 42.6 pmol/l, p = 0.1), P-SDS increased [median (IQR): - 1.4 (- 1.9, - 0.4) vs. - 0.3 (- 0.9, 0.4), p = 0.04], while eGFR increased. Five of 9 study group patients with available urine calcium had hypercalciuria. Five patients had nephrocalcinosis/lithiasis. Genetic analysis for pathogenic variants in CYP24A1, SLC34A1 and SLC34A3 had not been performed. CONCLUSIONS: Transient IIH was observed in infants with KHD, in association with hypophosphatemia, resembling SLC34A1 and SLC34A3 pathogenic variants' metabolic profile. A higher resolution version of the Graphical abstract is available as Supplementary information.
Authors: Karl P Schlingmann; Justyna Ruminska; Martin Kaufmann; Ismail Dursun; Monica Patti; Birgitta Kranz; Ewa Pronicka; Elzbieta Ciara; Teoman Akcay; Derya Bulus; Elisabeth A M Cornelissen; Aneta Gawlik; Przemysław Sikora; Ludwig Patzer; Matthias Galiano; Veselin Boyadzhiev; Miroslav Dumic; Asaf Vivante; Robert Kleta; Benjamin Dekel; Elena Levtchenko; René J Bindels; Stephan Rust; Ian C Forster; Nati Hernando; Glenville Jones; Carsten A Wagner; Martin Konrad Journal: J Am Soc Nephrol Date: 2015-06-05 Impact factor: 10.121
Authors: Karl P Schlingmann; Martin Kaufmann; Stefanie Weber; Andrew Irwin; Caroline Goos; Ulrike John; Joachim Misselwitz; Günter Klaus; Eberhard Kuwertz-Bröking; Henry Fehrenbach; Anne M Wingen; Tülay Güran; Joost G Hoenderop; René J Bindels; David E Prosser; Glenville Jones; Martin Konrad Journal: N Engl J Med Date: 2011-06-15 Impact factor: 91.245
Authors: Elisa De Paolis; Giovanni Luca Scaglione; Maria De Bonis; Angelo Minucci; Ettore Capoluongo Journal: Clin Chem Lab Med Date: 2019-10-25 Impact factor: 3.694
Authors: Galina Nesterova; May Christine Malicdan; Kaori Yasuda; Toshiyuki Sakaki; Thierry Vilboux; Carla Ciccone; Ronald Horst; Yan Huang; Gretchen Golas; Wendy Introne; Marjan Huizing; David Adams; Cornelius F Boerkoel; Michael T Collins; William A Gahl Journal: Clin J Am Soc Nephrol Date: 2013-01-04 Impact factor: 8.237
Authors: Isidro B Salusky; William G Goodman; Shobha Sahney; Barbara Gales; Ashley Perilloux; He-Jing Wang; Robert M Elashoff; Harald Jüppner Journal: J Am Soc Nephrol Date: 2005-06-08 Impact factor: 10.121